CompassNow live for financial advisors
Georgiamune stock

Georgiamune Stock

HealthTech

Looking to sell Georgiamune stock or options?

Founded: 2014Funding to Date: $168.8Mhttps://www.georgiamune.com

Operator of a clinical-stage biotechnology company intended to reprogram immune signaling pathways to restore immune homeostasis and fight cancer and autoimmune diseases. The company offers a proprietary target discovery platform that develops first-in-class targeted immunomodulatory therapeutics including novel monoclonal antibodies and small molecules designed to activate or down-modulate key immune pathways, enabling patients and healthcare providers to overcome treatment resistance, restore proper immune function and access effective, targeted treatments for hard-to-treat cancers and autoimmune conditions.

Notable investors include:
General Catalyst logo
Other investors include:

Prevail Private Capital, Hawktail, CJNV BioVentures, Catalio Capital Management, Lauder Partners, Parker Institute for Cancer Immunotherapy, Mubadala Capital, Verition Fund Management, Alexandria Venture Investments, Mamoura Diversified Global Holding.

Own Georgiamune stock or options?

Get an instant valuation

  • Completely free
  • 100% confidential & secure
  • Takes less than a minute
100% private & secure

Management Team

Sonia Quaratino Ph.DClinical Advisory Board
Ramy Ibrahim MDChief Medical and Strategy Officer
Jacques Banchereau Ph.DChief Innovation Officer
Mikayel Mkrichyan Ph.DSenior Vice President
Patrick ThompsonChief Financial Officer
Fred Ramsdell Ph.DMember of Scientific Advisory Board
Samir Khleif MDCo-Founder, Chief Executive Officer, President & Board Member

Board Members

Sean ParkerBoard Member
Elena VibochBoard Member
Paul BrownBoard Member
Dipchand NisharBoard Member

Georgiamune’s stock FAQs

Sell Georgiamune Stock? Get Liquidity, Defer the Taxes